Table 1 Patient Characteristics (n = 37)
|  |  | Curative group(n = 25) | Palliative group(n = 12) |
|---|---|---|---|
Median Age (range) | 68.4 (32–87) | 72 (44–82) | 67 (32–87) |
Gender | |||
 Male | 22 | 17 | 5 |
 Female | 15 | 8 | 7 |
Performance status | |||
 0 | 12 | 11 | 1 |
 1 | 19 | 13 | 6 |
 2 | 6 | 1 | 5 |
 3 | 0 | 0 | 0 |
Child-Pugh Classification | |||
 A | 27 | 20 | 7 |
 B | 27 | 5 | 5 |
Jaundice | |||
 yes | 26 | 21 | 5 |
 no | 11 | 4 | 7 |
Treatment intent | |||
 Curative | 25 |  |  |
 Palliative | 12 |  |  |
Median size of the tumor (range) (mm) | 57 (15–140) | 44 (15–140) | 60 (22–110) |
Number of tumor | |||
 single | 27 | 22 | 5 |
 multiple | 10 | 3 | 7 |
TNM stage (7th UICC) | |||
 I | 4 | 4 | 0 |
 II | 4 | 3 | 1 |
 III | 0 | 0 | 0 |
 IVa | 19 | 15 | 4 |
 IVb | 10 | 3 | 7 |
T stage | |||
 1 | 5 | 5 | 0 |
 2a | 6 | 4 | 2 |
 2b | 5 | 1 | 4 |
 3 | 1 | 1 | 0 |
 4 | 20 | 14 | 6 |
N stage | |||
 0 | 21 | 17 | 4 |
 1 | 16 | 8 | 8 |
M stage | |||
 0 | 27 | 22 | 5 |
 1 | 10 | 3 | 7 |
macroscopic subtype | |||
 Mass forming (MF) type | 19 | 13 | 6 |
 Intraductal growth (IG) type | 7 | 4 | 3 |
 Periductal infiltrating (PI) type | 11 | 8 | 3 |
Total dose | |||
 66.0 GyE in 10 Fraction (BED*:109.6 Gy) | 1 | 1 | 0 |
 72.6 GyE in 22 Fraction (BED:96.6 Gy) | 21 | 19 | 2 |
 74.0 GyE in 37 Fraction (BED:88.8 Gy) | 5 | 2 | 3 |
 Other (BED < 88.8Gy) | 10 | 3 | 7 |
Concurrent chemotherapy | |||
 TS-1 | 15 | 11 | 4 |
 Gemcitabine | 1 | 1 | 0 |
 None | 21 | 13 | 8 |
Adjuvant Chemotherapy | |||
 TS-1 | 10 | 7 | 3 |
 Cisplatine + Gemcitabine | 5 | 4 | 1 |
 Gemcitabine | 4 | 2 | 2 |
 None | 18 | 11 | 7 |